Semaglutide Reduces Murine Blood Pressure Through the Vascular Smooth Muscle GLP-1 Receptor - PubMed
4 hours ago
- #Endocrinology
- #Metabolism
- #Cardiology
- Semaglutide, a GLP-1 receptor (GLP-1R) agonist, reduces blood pressure (BP) in mice through vascular smooth muscle cells (VSMCs).
- The BP-lowering effect of semaglutide is independent of GLP-1Rs in endothelial or immune cells.
- VSMC GLP-1R is crucial for semaglutide's effects on glomerular filtration rate, natriuresis, and vasorelaxation but not for weight loss or blood glucose control.
- Semaglutide induces proteomic changes in renal artery and kidney related to platelet aggregation, fibrin clot formation, lipid metabolism, and pro-apoptotic signaling.
- The study identifies VSMCs as a key target for GLP-1R activation in BP regulation and renal function.